Tectonic Therapeutic reported a net loss of $15.9 million for the first quarter of 2025, compared to a net loss of $15.2 million in the same period last year. The company's cash and cash equivalents increased to $306.2 million, providing a cash runway into Q4 2028. Key business highlights included positive interim results from the TX45 Phase 1b Part A trial and the initiation of Part B, along with the ongoing APEX Phase 2 trial.

Tectonic Therapeutic reported a net loss of $12.4 million for Q4 2024, an increase from $7.9 million in Q4 2023. The company's cash and cash equivalents stood at $141.2 million as of December 31, 2024, with a private placement in February 2025 expected to extend the cash runway into Q4 2028. Key business highlights included positive interim results from the TX45 Phase 1b trial and the first subject enrolled in the TX45 Phase 1b Part B trial.

Tectonic Therapeutic reported a net loss of $17.7 million for the third quarter ending September 30, 2024, with cash and cash equivalents totaling $159.1 million. The company is advancing its pipeline, including the initiation of the APEX Phase 2 clinical trial and continued enrollment in the Phase 1b hemodynamic trial for TX45.

Tectonic Therapeutic announced its second quarter 2024 financial results, highlighting the advancement of TX45 into a Phase 2 clinical trial, U.S. IND clearance for TX45, and the completion of a reverse merger with AVROBIO including a $130.7 million private placement. Cash and cash equivalents were $185.1 million as of June 30, 2024.

AVROBIO reported a net loss of $25.0 million for the first quarter of 2023, compared to a net loss of $29.8 million for the same period in 2022. The company's cash and cash equivalents totaled $72.3 million as of March 31, 2023, and are expected to fund operations into the first quarter of 2024.

AVROBIO reported a net loss of $25.0 million for the fourth quarter of 2022. As of Dec. 31, 2022, AVROBIO had $92.6 million in cash and cash equivalents.

AVROBIO reported a net loss of $23.0 million for the third quarter of 2022, compared to a net loss of $32.6 million for the same period in 2021. The decrease was attributed to a reduction in research and development expenses. The company's cash and cash equivalents as of September 30, 2022, are expected to fund operating expenses and capital expenditure requirements into the first quarter of 2024.

AVROBIO reported a net loss of $28.1 million for Q2 2022, with reduced research and development expenses. The company is advancing its gene therapy pipeline, with key milestones expected in the second half of the year, including regulatory interactions and clinical data updates for cystinosis and Gaucher disease programs.

AVROBIO reported a net loss of $29.8 million for the first quarter of 2022. The company's cash and cash equivalents are expected to fund operating expenses and capital expenditure requirements into the first quarter of 2024.

AVROBIO reported a net loss of $28.2 million for the fourth quarter of 2021. The company's cash runway is expected to last into Q1 2024.

AVROBIO reported a net loss of $32.6 million for the third quarter of 2021, driven by decreased research and development expenses, partially offset by increased general and administrative expenses. They ended the quarter with $201.4 million in cash and cash equivalents.

AVROBIO reported a net loss of $31.4 million for the second quarter of 2021, driven by increased research and development expenses as well as increased general and administrative expenses. As of June 30, 2021, AVROBIO had $226.4 million in cash and cash equivalents.